Aclarion Receives Pinnacle Award for AI Innovation

Rhea-AI Summary

Aclarion (NASDAQ: ACON) received a Diamond Pinnacle Award for AI Innovation in Clinical Decision AI on April 14, 2026, recognizing its Nociscan MR spectroscopy–based SaaS platform for identifying biochemical markers of discogenic chronic low back pain.

The company cites a 97% surgical success rate when all Nociscan-positive discs are treated and notes global prevalence estimates of 266 million people with degenerative spine disease and low back pain.

Positive

• Diamond Pinnacle Award for AI Innovation enhances external validation
• Nociscan reports 97% surgical success rate when positive discs are treated
• Cloud-based SaaS enables rapid deployment across imaging centers and health systems

Negative

• None.

News Market Reaction – ACON

-1.25%

3 alerts

-1.25% Session close to close

-9.2% Trough Tracked

$7.33M Market Cap

0.7x Rel. Volume

In the Apr 14 session, ACON declined 1.25%, reflecting a mild negative market reaction. Argus tracked a trough of -9.2% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds external validation for Aclarion’s Nociscan platform, highlighting its AI-dri...

Analysis

This announcement adds external validation for Aclarion’s Nociscan platform, highlighting its AI-driven, MR spectroscopy‑based approach and reported 97% surgical success when all Nociscan‑positive discs are treated. It reinforces the company’s focus on a large chronic low back pain population of 266 million people globally. In context with prior AI-tag milestones and trials, investors may watch adoption trends, clinical evidence, and reimbursement developments as key next steps.

Key Figures

Global cLBP population: 266 million people Surgical success rate: 97%

2 metrics

Global cLBP population 266 million people Worldwide degenerative spine disease and low back pain burden cited in release

Surgical success rate 97% Clinical data when all Nociscan-positive discs are treated alongside other diagnostics

Previous AI Reports

3 past events · Latest: Sep 27 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 27	Clinical AI study	Positive	+0.4%	Nociscan AI featured in Modic changes study for chronic low back pain.
Sep 12	AI tech milestones	Positive	+15.4%	Corporate update on Nociscan AI milestones, coverage, partnerships, and trials.
Aug 21	AI trial launch	Positive	-0.6%	Launch of CLUE trial to quantify Nociscan AI’s impact on surgical plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

AI-tag announcements have generally produced modestly positive reactions, with one small negative divergence.

Recent Company History

Over recent AI-related updates, Aclarion has highlighted Nociscan’s role in clinical studies, technology milestones, and new trials. On Aug 21, 2024, the CLUE trial launch to measure how Nociscan AI data changes surgical plans saw a -0.61% move. Corporate AI technology milestones on Sep 12, 2024 led to a stronger 15.38% gain, while a study on Modic changes on Sep 27, 2024 drew a mild 0.4% uptick. Today’s AI innovation award fits this ongoing validation of Nociscan’s decision-support role.

Key Terms

biomarkers, augmented intelligence, mr spectroscopy, cloud-based algorithms, +3 more

7 terms

biomarkers medical

"leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

augmented intelligence technical

"leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help"

Augmented intelligence combines human skills with advanced technology to enhance decision-making and problem-solving. It acts like a helpful partner that provides insights and suggestions, allowing people to make better choices more quickly. For investors, this means smarter analysis, improved efficiency, and the ability to respond to market changes with greater confidence.

mr spectroscopy medical

"Nociscan solution to bring objective, MR spectroscopy‑based biomarker analysis into routine"

MR spectroscopy is a scientific technique that uses magnetic fields and radio waves to analyze the chemical composition of materials, including biological tissues. It helps researchers identify and measure the presence of different molecules, providing insights into health, disease, or material properties. For investors, understanding MR spectroscopy can be important when evaluating innovations in medical technology or pharmaceutical developments that may impact healthcare markets.

cloud-based algorithms technical

"a new model of MedTech innovation built on scalable, cloud-based algorithms."

Cloud-based algorithms are sets of automated rules or models that run on remote servers to analyze large amounts of data and make predictions or decisions, accessed over the internet rather than from a local computer. For investors they matter because they can deliver faster, cheaper and more scalable insights—like using a shared, powerful GPS to navigate markets—but also create reliance on third-party providers and raise data security, cost and regulatory risks that can affect a company’s performance.

biochemical data medical

"Providing physicians with objective biochemical data has the potential to fundamentally"

Measurements taken from biological samples or tests that show chemical changes or levels—such as proteins, hormones, metabolites, or enzyme activity—used to track how a drug, therapy, or medical device affects the body. For investors, biochemical data act like a medical thermometer or scorecard: they provide objective evidence of effectiveness, safety, or mode of action, helping assess development progress, regulatory chances, and commercial potential.

intervertebral discs medical

"uses MR spectroscopy to identify chemical biomarkers within intervertebral discs."

Intervertebral discs are the soft, cushion-like pads sitting between the bones of the spine that absorb shocks and allow the back to bend and twist, similar to the rubber cushions between metal parts in a machine. They matter to investors because damage or degeneration of these discs drives demand for medical treatments, devices, diagnostics and long-term care, which can affect sales, regulatory risk and market size in health-related companies.

saas platform technical

"first evidence-supported SaaS platform to noninvasively help physicians distinguish"

A SaaS platform is software delivered over the internet that customers access through a subscription instead of installing and running it on their own computers; the provider hosts, updates, and secures the application remotely. Investors care because SaaS businesses often generate predictable, recurring revenue and can scale quickly as more customers sign up, making them easier to value and potentially more profitable over time—similar to a utility that collects steady fees as its user base grows.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Recognition Follows 2025 HLTH Digital Health Award for Nociscan

Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market

BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has been awarded a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category. The award recognizes the company’s use of AI in its Nociscan solution for chronic low back pain, one of healthcare’s most pervasive and costly challenges.

This recognition follows Aclarion’s earlier selection as a 2025 Digital Health Awards at HLTH winner, where Nociscan was honored for its potential to transform the evaluation and management of discogenic low back pain. Together, the Pinnacle and HLTH awards reflect growing external validation of Aclarion’s mission to bring objective, MR spectroscopy‑based biomarker analysis into routine clinical decision‑making while advancing a new model of MedTech innovation built on scalable, cloud-based algorithms.

“Receiving recognition from both the Pinnacle Awards and HLTH underscores the accelerating momentum behind our technology,” said Brent Ness, CEO of Aclarion. “Chronic low back pain remains one of the most challenging and costly conditions in medicine. Providing physicians with objective biochemical data has the potential to fundamentally improve how discogenic pain is evaluated and treated.”

Aclarion’s flagship platform, Nociscan, uses MR spectroscopy to identify chemical biomarkers within intervertebral discs. These biomarkers are processed through proprietary algorithms that classify whether a disc’s biochemical profile is consistent with a painful or non‑painful disc. Physicians use this information—alongside imaging, clinical evaluation, and their own expertise—to optimize treatment planning for patients with discogenic low back pain.

The company continues to expand adoption of Nociscan among spine specialists seeking more objective tools for evaluating chronic low back pain. Since Nociscan is delivered through a cloud-based analytics platform, it can be rapidly deployed across imaging centers and health systems without requiring new hardware infrastructure.

Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used alongside other diagnostic tools, clinical data demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.

For more News from Aclarion, please visit: Latest News

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com

FAQ

What award did Aclarion (ACON) receive on April 14, 2026?

Aclarion received the Diamond Pinnacle Award for AI Innovation in Clinical Decision AI. According to the company, the award recognizes Nociscan's use of AI to support clinical decision-making for discogenic low back pain.

What is Nociscan and how does it work for ACON patients?

Nociscan is an MR spectroscopy–based SaaS platform that identifies chemical biomarkers in intervertebral discs. According to the company, proprietary algorithms classify discs as painful or nonpainful to aid physicians alongside imaging and clinical evaluation.

What clinical outcome does Aclarion (ACON) report for Nociscan-guided treatment?

The company reports a 97% surgical success rate when all Nociscan-positive discs are treated. According to the company, this figure reflects clinical data when Nociscan findings were used alongside other diagnostic tools.

How quickly can health systems deploy Aclarion's Nociscan (ACON) solution?

Nociscan is delivered via a cloud-based analytics platform and can be rapidly deployed without new hardware. According to the company, this SaaS model allows swift rollout across imaging centers and health systems.

How large is the market Aclarion (ACON) targets with Nociscan?

Aclarion cites approximately 266 million people worldwide affected by degenerative spine disease and low back pain. According to the company, this underscores the substantial clinical need for objective tools to evaluate discogenic pain.